Bloomberg (01/06/12) Fisk, Margaret Cronin
Johnson & Johnson will pay more than $1 billion to the U.S. and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal, according to insiders. The U.S. government has been investigating Risperdal sales practices since 2004, including allegations the company marketed the drug for unapproved uses. Risperdal is a member of a class of drugs, known as atypical antipsychotics, that includes Eli Lilly’s Zyprexa and AstraZeneca’s Seroquel. Lilly, AstraZeneca and two other J&J competitors making these drugs have paid $2.7 billion to resolve government marketing claims, particularly that the companies pushed the drugs for unapproved uses.